Ultralife (ULBI) files 8-K on Q3 2025 earnings press release

Ultralife Corporation filed a current report to announce that it has released financial results for its third quarter ended September 30, 2025.

Rhea-AI Filing Summary

Ultralife Corporation filed a current report to announce that it has released financial results for its third quarter ended September 30, 2025. The company states that these results are presented in a press release dated November 18, 2025, which is attached as Exhibit 99.1. The filing is signed by the Chief Financial Officer and Treasurer, highlighting that this is the formal disclosure of the latest quarterly performance details through the accompanying press release.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ultralife Corporation (ULBI) report in this Form 8-K?

Ultralife Corporation reported that it issued a press release containing its financial results for the third quarter ended September 30, 2025, and furnished that release as an exhibit.

Which period do the latest Ultralife (ULBI) financial results cover?

The latest financial results discussed by Ultralife Corporation cover its third quarter ended September 30, 2025.

Where can investors find the detailed Q3 2025 results for Ultralife Corporation?

Investors can find the detailed Q3 2025 results in the press release attached as Exhibit 99.1 to this report.

What is Exhibit 99.1 in Ultralife Corporation’s 8-K filing?

Exhibit 99.1 is a press release of Ultralife Corporation dated November 18, 2025, which contains the company’s third quarter 2025 financial results.

Who signed Ultralife Corporation’s November 18, 2025 Form 8-K?

The Form 8-K was signed on behalf of Ultralife Corporation by Philip A. Fain, the company’s Chief Financial Officer and Treasurer.

What exchange does Ultralife Corporation (ULBI) common stock trade on?

Ultralife Corporation’s common stock, par value $0.10 per share, trades on the NASDAQ Stock Market under the symbol ULBI.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/18/2025 - 07:30 AM Learn about SEC filing dates

false 0000875657 0000875657 2025-11-18 2025-11-18

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
November 18, 2025
Date of Report (Date of Earliest Event Reported)
ULTRALIFE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware	000-20852	16-1387013
(State of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
2000 Technology Parkway, Newark, New York 14513
(Address of principal executive offices) (Zip Code)
(315) 332-7100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.10 par value per share		ULBI		NASDAQ Stock Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On November 18, 2025, Ultralife Corporation issued a press release regarding the financial results for its third quarter ended September 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

Item 9.01 Financial Statements, Pro Forma Financials and Exhibits

(d) Exhibits.

Exhibit Number		Exhibit Description
99.1		Press Release of Ultralife Corporation dated November 18, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 18, 2025		ULTRALIFE CORPORATION
	By:	/s/ Philip A. Fain
		Philip A. Fain
		Chief Financial Officer and Treasurer